In a landmark decision poised to reshape access to one of the world’s most sought-after medications, Health Canada has granted…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
In a landmark decision poised to reshape access to one of the world’s most in-demand medications, Health Canada has granted…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The pharmaceutical landscape for diabetes and weight management medications has undergone a significant shift with Health Canada’s authorization of Dr.…
Read More
Canada Makes History as First G7 Nation to Approve Generic Semaglutide, Sparking Global Debate on Patent Enforcement and Drug Access
In a landmark decision poised to reshape the landscape of diabetes and obesity management, Health Canada has granted authorization to…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide as Novo Nordisk Patent Lapses
In a landmark decision poised to reshape the pharmaceutical landscape and significantly impact patient access and healthcare costs, Health Canada…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant reordering in fiscal year 2025, as revealed by the latest "Pharma 50"…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The Canadian healthcare landscape is poised for a significant transformation with Health Canada’s authorization of Dr. Reddy’s Laboratories’ generic semaglutide…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025.
The pharmaceutical industry witnessed a significant shift in its commercial landscape during Fiscal Year 2025, with Merck’s oncology powerhouse, Keytruda…
Read More
New Study Reveals Oral Semaglutide Outperforms Orforglipron in Weight Loss and Tolerability
Findings presented at the 33rd European Congress on Obesity in Istanbul, Turkey, on May 15th, have provided a crucial comparative…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide Following Novo Nordisk Patent Lapse, Paving Way for Enhanced Access and Affordability
In a landmark decision poised to significantly reshape the pharmaceutical landscape for diabetes and obesity management, Health Canada has granted…
Read MoreYOU MAY HAVE MISSED
